首页> 美国卫生研究院文献>other >Five-year risk of recurrence following treatment of CIN2 CIN3 or AIS: performance of HPV and Pap cotesting in post-treatment management

【2h】

Five-year risk of recurrence following treatment of CIN2 CIN3 or AIS: performance of HPV and Pap cotesting in post-treatment management

机译：CIN2CIN3或AIS治疗后的五年复发风险：HPV和Pap共同测试在治疗后管理中的表现

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

ObjectiveAfter excisional treatment, CIN2+ can recur. It is not clear how many negative post-treatment Pap or cotest results are needed to assure adequate safety against CIN2+, prior to return to extended retesting intervals.

机译：目的经切除治疗后，CIN2 +可复发。目前尚不清楚在返回延长的复检间隔之前，需要多少阴性的治疗后Pap或联合测试结果以确保足够的抗CIN2 +安全性。

著录项

期刊名称 other
作者
Hormuzd A. Katki; Mark Schiffman; Philip E. Castle; Barbara Fetterman; Nancy E. Poitras; Thomas Lorey; Li C. Cheung; Tina Raine-Bennett; Julia C. Gage; Walter K. Kinney;
展开▼
作者单位

展开▼
年(卷),期 -1(17),5 0 1
年度 -1
页码 S78–S84
总页数 12
原文格式 PDF
正文语种
中图分类
关键词
Human Papillomavirus (HPV) cancer prevention Pap cervical intraepithelialneoplasia (CIN) Hybrid Capture 2 (HC2) post-treatment test of cure;

机译：人乳头瘤病毒（HPV）;癌症预防;宫颈癌;宫颈癌;宫颈上皮内肾病（CIN）;Hybrid Capture 2（HC2）;治疗后;治愈测试;

相似文献

外文文献
中文文献
专利

1. Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS: Performance of HPV and Pap Cotesting in Posttreatment Management [J] . Hormuzd A. Katki, Mark Schiffman, Philip E. Castle, Journal of lower genital tract disease. . 2013,第Suppla期

机译：CIN 2，CIN 3或AIS治疗后的五年复发风险：HPV和巴氏试验在治疗后管理中的表现
2. Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models. [J] . K Syrj?nen, I Shabalova, L Sarian, European journal of gynaecological oncology . 2012,第1期

机译：正如竞争风险回归模型所揭示的，对于事件CIN1，CIN2和CIN3，高危人类乳头瘤病毒（HPV）感染的协变量是不同的。
3. Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines [J] . Hormuzd A. Katki, Mark Schiffman, Philip E. Castle, Journal of lower genital tract disease. . 2014,第Suppla期

机译：将CIN 3+风险作为基准将HPV和子宫颈抹片检查纳入宫颈筛查和管理指南
4. 'Lesion-habitat' Radiomics to distinguish Radiation Necrosis From Tumor Recurrence on post-treatment MRI in Metastatic Brain Tumors [C] . Ramon Correa, Qiu Lei, Jonathan Chcn, Medical Imaging Conference . 2020

机译：在转移性脑肿瘤的治疗后MRI上，“ Leath-habitat”放射线学可区分放射坏死与肿瘤复发
5. Prediction of Clostridium Difficile Infection Recurrence and Risk-Based Heterogeneity of Treatment Effect of Vnacomycin vs Fidaxomicin. [D] . Alraddadi, Basem. 2013

机译：瓦克霉素与非达霉素的难治性梭状芽胞杆菌感染复发的预测及基于风险的异质性。
6. Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines [O] . Hormuzd A. Katki, Mark Schiffman, Philip E. Castle, -1

机译：以CIN3 +风险为基准将HPV和Pap共同测试纳入宫颈癌筛查和管理指南
7. Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort [O] . Jesper Bonde, Fabio Bottari, Valentin Parvu, 2019

机译：HPV基因型在欧洲推荐队列中的CIN2和≥CIN3的基线风险的贝叶斯分析

Five-year risk of recurrence following treatment of CIN2 CIN3 or AIS: performance of HPV and Pap cotesting in post-treatment management

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅